Molecular theranostics: prostate cancer and neuroendocrine tumor treatment gets personal
Prostate cancer is far more prevalent than neuroendocrine tumors. The American Cancer Society estimates that there will be about 161,360 new cases of prostate cancer and about 26,730 deaths from the disease this year.
“When talking about prostate cancer that recurs and becomes hormone resistant, you have to lock all of the hormones in the body, which is usually done with medication, but even with these medications the tumors reoccur,” says Czernin.
The prostate-specific membrane antigen (PSMA) protein, which is found on the surface of prostate cancer and metastatic cells, was first discovered in the 1980s. It was originally labeled with Ga-68 and only used for diagnostic purposes, but eventually it was labeled with Lu-177 to also be used to treat metastatic prostate cancer.
Contact Us
NuView Life Sciences, Inc
1314 E. Las Olas Blvd
Ft Lauderdale FL 33301